Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to new employees. On June...
-- Dave Lowrance to Step Down as Chief Financial and Administrative Officer -- -- Robert Lutz to Assume Combined Role of Chief Operating and Financial Officer --
Savara Inc. (Nasdaq: SVRA ) (the “Company”), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of the management team...
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at the ATS 2026 International Conference that is taking...
-- Data Were Presented at the American Thoracic Society (ATS) International Conference 2026 -- -- All Patients Receive Molgramostim During the OL Treatment Period;...
-- Data Were Presented in an Oral Presentation at the American Thoracic Society (ATS) International Conference 2026 --
Achieved Regulatory Milestones for the MOLBREEVI* Development Program in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP): ...
Barchart Research What to Expect from SVRA Earnings SVRA Generated May 11, 2026 Current Price $5.14 EPS Estimate $$-0.14 Consensus Rating Strong Buy Average Move 5.61% Savara's Regulatory Timeline Faces...
Savara Inc. (Nasdaq: SVRA ) (the “Company”), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of the management team...
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to new employees. On April...